to community-dwelling people beyond age 85 years. [15] [16] [17] [18] [19] Even frail older NH residents may benefit. 20 Data from community-dwelling older adults have shown that use of secondary prevention medications after AMI decreases as age increases. [21] [22] [23] [24] [25] These studies have presented conflicting data on whether functional limitations, frailty, and other geriatric syndromes are associated with even lower rates of secondary prevention medication use, [21] [22] [23] [24] [25] but substantially less is known about use of these medications in older NH residents. Because NH residents have different clinical characteristics and systems of care than their community-dwelling counterparts, patterns of medication use are often distinct.
A handful of prior studies in the NH setting found low use of secondary prevention medications. [26] [27] [28] [29] [30] [31] Several important limitations of these prior NH studies constrain our understanding of current patterns of secondary prevention use. Because the studies used older data (from the 1990s), had small sample sizes, relied on hospital records only, and applied several very restrictive exclusion criteria, their generalizability to the current, national population of NH residents in the United States is unclear. The studies also did not attempt to distinguish continuation of secondary prevention therapies taken before AMI (prevalent use) from new prescribing after AMI. Furthermore, there have been general improvements in adherence to ischemic heart disease-related guideline recommendations in the United States since publication of prior studies. Little evidence is available to determine whether prescribing practices for NH residents have changed in tandem. Understanding recent prescribing practices in the NH setting is essential for identifying potential gaps in the quality of care and corresponding opportunities to address gaps efficiently.
The objective of this study was to describe the epidemiology of secondary prevention medication use after AMI in a national sample of U.S. nursing homes. We focused on individuals who were nonusers of beta-blocker and statin therapy to understand how NH prescribers respond to widely accepted clinical practice guidelines that recommend initiating these medications after AMI. It was hypothesized that older age, worse functional status, and worse cognition would be associated with initiation of fewer secondary prevention medications.
METHODS

Data Sources
We linked the following national datasets: Medicare feefor-service denominator (eligibility) information, Medicare Part A inpatient hospital claims, Medicare Part D prescription drug claims, and Minimum Data Set (MDS) 2.0. The MDS is a comprehensive, clinical assessment instrument used to document the health status of nursing home residents, including demographic, medical, functional status, psychological, and cognitive status information. [32] [33] [34] Online Survey Certification and Reporting (OSCAR) data were used for facility-level information, including NH characteristics, staffing levels, and quality measures. 35, 36 A previously validated residential history file algorithm was used to track the timing and location of health service use. 37 
Study Population
This was a retrospective inception cohort study of a previously established 20, 38 national cohort of long-stay NH residents without a history of AMI who were hospitalized for AMI, had not taken beta-blockers or statins for at least 4 months before their AMI, and were readmitted to a U.S. NH directly after hospital discharge between May 1, 2007 and December 31, 2010 (Supplementary Figure S1) . We selected previous nonusers to enable evaluation of the decision to initiate secondary prevention medications after AMI, distinct from the decision to continue these agents in individuals who had been taking them before their AMI. Additional details of the cohort have been previously published.
20,38
Measurement of Secondary Prevention Medication Use
Oral beta-blocker and statin medications (Supplementary  Table S1 ) were identified according to generic name in Medicare Part D prescription drug claims. 39 The categorical secondary prevention medication use variable had 3 distinct levels: 0, 1, or 2 medication classes used. Details of the complementary approaches used to ascertain secondary prevention medication exposure, including a validation cohort with complete prescription drug dispensing data from a large, national private NH chain (HCR ManorCare, Inc., Toledo, OH), are described elsewhere. 20, 38 In brief, those approaches are important because Medicare Part D drug dispensing claims are not generated while NH residents receive care through the skilled nursing facility (SNF) benefit.
20,38
Measures of Resident and NH Characteristics
Variables that could potentially predict secondary prevention medication use included demographic characteristics from Medicare enrollment files, concomitant medication use from Part D claims, and comorbidities from Part A claims, all measured in the year before AMI. Part A claims were also used to document recent hospital course (including procedures), severity of cardiovascular disease, and Elixhauser Comorbidity Index score. 40 Pre-AMI medication use was included as a marker of residents' clinically active conditions and risk of future clinical events (e.g., residents prescribed warfarin may be at higher risk of future cerebrovascular events).
A number of MDS items have been structured into reliable, valid measures of resident functional status. [41] [42] [43] Each resident's level of functional impairment was estimated using the MDS activities of daily living (ADL) score documented in the assessment closest to the AMI date in the 90 days before the AMI. This summary measure indicates the degree of dependence on staff assistance in seven areas of ADL function (bed mobility, transfer, locomotion, dressing, eating, toilet use, personal hygiene) and ranges from 0 (no assistance required) to 28 (total dependence in ADL functioning). 44 Cognitive function was measured using the Cognitive Performance Scale; scores range from 0 (intact) to 6 (severe impairment). 42 Other geriatric syndromes (weight loss, falls, presence and frequency of pain, Changes in Health, End-Stage Disease, Signs, and Symptoms Scale (CHESS) score) and do-not-resuscitate (DNR) order status were also measured in the MDS. There are no explicit contraindications to using more secondary prevention medications, yet we examined potential contraindications to using individual medication classes to confirm our hypothesis that they were only weakly related to the number of medications prescribed.
Information on facility characteristics and indicators of care quality was obtained from the most recent OSCAR survey before the acute AMI hospitalization.
Statistical Analyses
Univariable associations between potential predictors and secondary prevention medication initiation were first evaluated using ordinal logistic regression models to estimate proportional odds ratios (PORs). Ordinal logistic regression models were selected because the number of secondary prevention medication classes an individual receives can be logically ordered from smallest to largest, and the cumulative probability was of greater interest. 45 A multilevel multivariable ordinal logistic regression model was used to test the hypothesis that certain individual and facility factors would be independently associated with secondary prevention medication prescribing for residents after AMI. 45 Because residents are clustered within NHs, we included random intercepts for facilities in the model to ensure more accurate standard errors. 46 Resident and facility characteristics were modeled as fixed effects. Multivariable analyses were adjusted for the full set of variables shown in Tables 3 and 4 , plus additional variables.
Stability Analyses
We also evaluated several alternate approaches to determine whether our results were robust to various decisions about study design and estimation. Renin-angiotensinaldosterone system (RAAS) medications (angiotensinconverting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs)) are indicated after AMI primarily for individuals with heart failure, left ventricular systolic dysfunction (ejection fraction ≤0.40), hypertension, and diabetes mellitus. Because these medications are not indicated for everyone, we included them as a possible secondary prevention medication class in stability analyses. 4 Guideline-recommended antiplatelet medications included clopidogrel and aspirin. Aspirin is available without a prescription and is underascertained in Medicare claims, thus we did not include antiplatelet medications in the primary outcome definition. Instead, we conducted a stability analysis in which the outcome variable included beta-blockers, statins, and antiplatelet drugs. Finally, we used multinomial logistic regression models for estimation as an alternative to ordinal logistic regression models that does not require the proportional odds assumption.
Software
Data were analyzed using SAS version 9.4 (SAS Institute, Inc., Cary, NC) and Stata version 14.0 (Stata Corp., College Station, TX).
Ethics Approval
The institutional review boards of Brown University, the University of California San Francisco, and the San Francisco Veterans Affairs Health Care System approved the study protocol.
RESULTS
Residents readmitted to the NH after AMI had a mean age of 84; 28% were male, 83% were non-Hispanic white, 53% had a DNR order, and 72% returned to the NH on No secondary prevention medications were dispensed to 34% of those who returned to the NH on the Medicare SNF benefit and 44% of those discharged directly to longterm care (LTC). There was variation in secondary prevention medication use according to geographic region, ranging from 31.4% of residents in the Northeast to 40.8% of residents in the South receiving no medications after AMI.
In univariable analyses, several factors were meaningfully associated with initiation of more secondary prevention medications (Tables 3 and 4, Supplementary  Table S4 ). Older age and diagnoses of angina pectoris and unstable angina were predictive of receiving fewer secondary prevention medications. Functional and cognitive impairment before AMI were predictive of less secondary prevention medication use in univariable analyses. Coronary revascularization or angioplasty during the AMI hospitalization was associated with twice the likelihood of receiving more secondary prevention medications. These patterns persisted in multivariable analyses; residents with severe functional and cognitive impairment (functional, POR = 0.77, 95% confidence interval (CI) = 0.69-0.86; cognitive, POR = 0.79, 95% CI = 0.70-0.89) and those with a DNR order (POR = 0.90, 95% CI = 0.83-0.98) were less likely to receive secondary prevention medications after returning to the NH after AMI. Older age remained a significant predictor of less secondary prevention medication use in multivariable analyses, with the oldest residents (≥95) receiving the fewest medications (POR = 0.48, 95% CI = 0.40-0.57 vs 65-74). Female residents were significantly less likely to receive secondary prevention medications (POR = 0.88, 95% CI = 0.80-0.96). Non-Northeast geographic region of residence was independently associated with less secondary prevention medication use, and coronary revascularization or angioplasty was associated with more (Tables 3 and 4,  Supplementary Table S4 ). Elixhauser Comorbidity Index and CHESS score were not independently associated with greater secondary prevention medication use.
Various NH characteristics examined were also not independently associated with secondary prevention medication use (Supplementary Table S4 ). When the analyses were stratified according to initial post-AMI type of NH care, the independent associations between predictors and secondary prevention medication initiation were similar for residents who returned to the NH through the SNF and LTC pathways of care (data not shown).
Results from the stability analyses examining RAAS inhibitors as an included secondary prevention medication class (Supplementary Tables S5, S6 , and S7); using multinomial logistic regression models (Supplementary  Table S8 ); and examining beta-blocker, statin, and antiplatelet use after AMI (Supplementary Tables S9 and S10) were also consistent with the main analysis.
DISCUSSION
Thirty-seven percent of this national sample of older NH residents did not receive any secondary prevention medications within 30 days of returning to the NH after AMI. Advanced age, functional dependence, and cognitive impairment explained some of the variation in secondary prevention medication use. Few other factors were as strongly predictive.
The presence of characteristics that were strongly predictive of not receiving secondary prevention medications in our study suggests that many providers do not expect several important subgroups of NH residents to benefit from use of more treatments. The use of fewer guidelinerecommended medications in residents with advanced age, functional dependence, and cognitive impairment may also suggest that providers are concerned that the potential harms of using more medications in those groups do not outweigh the benefits or that more medication use is inconsistent with the goals of care. 20 Because of the exclusion of older NH residents from RCTs, little information is available to support the idea that such residents would benefit less from treatment (perhaps because of the limited life expectancy of these individuals) or be more susceptible to harms after AMI, although these are generally reasonable assumptions.
2,47-50 Our findings reveal an opportunity for future pharmacoepidemiological research to improve the evidence base for using more (or fewer) secondary prevention medications after AMI in the NH setting. Previous studies have examined the benefits and harms of initiating individual secondary prevention medication classes after AMI in the NH setting. 20 For example, our research group has demonstrated that use of beta-blockers is associated with lower risk of mortality and greater risk of functional decline, especially in those with pre-AMI cognitive or functional impairment, 20 but understanding the effect of using more medications is a distinct and important endeavor.
Prior studies of older ambulatory populations have reported underuse of secondary prevention medications after AMI. 3, 15, 17, 18, [22] [23] [24] [25] Likewise, studies of NH populations have reported underuse of individual secondary prevention medication classes. [26] [27] [28] [29] [30] [31] The older estimates are difficult to compare directly with those from our study because they examined individual drug classes, but a recently conducted study examined number of drug classes initiated after AMI using claims data from 2007 to 2008 to examine secondary prevention medication use in elderly (mean age 78.1) Medicare beneficiaries discharged to a community-based setting from acute care hospitals in the United States after AMI. 23 The main finding of their study was that pre-AMI functional impairment was associated with less use of post-AMI secondary prevention medications, although they found use of more medications than what we report, which is probably because their study population was younger, less multimorbid, and more functionally intact. It may also be due in part to our exclusion of individuals who were taking secondary prevention medications before the index AMI, thereby enriching the population with individuals who have a contraindication to one of the drug classes or who may have another reason (e.g., goals of care, suboptimal prescribing) for not receiving the drugs. Using claims-based measures of functional capacity, the other study 23 reported qualitatively similar relationships between functional status and secondary medication use, whereby older adults with worse functional status were less likely to receive more medications after AMI.
This study has some limitations. First, aside from a validation cohort from HCR ManorCare, Inc., secondary prevention medication use was unobservable during the SNF stay in the NH. As a consequence, the use of secondary prevention medications may have been misclassified, although the validation cohort from HCR ManorCare, Inc., for whom medication use during SNF stay was observable, suggests that our approach to classifying secondary prevention medication use will be accurate for all but a small minority of individuals. Second, the data were from 2007 to 2010, but given the lack of substantial changes in guidelines, guideline dissemination, or NH standards of practice, it is unlikely that prescribing practices have changed markedly in the intervening years. Third, we focused our study on people who were not using secondary prevention medications before AMI to evaluate new prescribing decisions about these drugs. Because individuals who use secondary prevention medications before AMI are likely to continue these drugs after AMI, overall use of secondary prevention medications after AMI is likely to be higher, and we are unable to compare our observed rates directly with those of other studies that combine incident and prevalent secondary prevention medication use. Fourth, we were unable to accurately differentiate ST-elevation MI (STEMI) from non-STI-elevation MI (NSTEMI), but MI type may have influenced prescribing. Fifth, although the data included measures of several potential contraindications to secondary prevention medication use, including obstructive lung disease and concurrent use of calcium channel blockers with atrioventricular node-blocking activity, the data sources are unable to robustly capture other contraindications such as symptomatic bradycardia or hypotension.
In summary, many elderly NH residents do not receive secondary prevention medications after AMI. The low use of secondary prevention medications in older residents and those with impaired cognition and poor functional status may be indicative that providers expect these subgroups of NH residents with AMI to benefit less from more aggressive treatment. This is not surprising given the absence of evidence documenting the benefits of using more secondary prevention medications in older NH residents. The relatively low use may suggest ongoing concern about the balance of these benefits and harms, especially detrimental effects on person-centered outcomes, and resident or provider assessment that use of the drugs is inconsistent with the goals of care. Given practical and ethical considerations, it is unlikely that any RCTs to study the effects of using more of the recommended secondary prevention medications will be forthcoming. Rather, rigorous observational studies will be critical for developing an evidence base to evaluate the effectiveness and safety of secondary prevention medication use in older NH residents.
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